Clinical Trial Update: A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin [Phase 2]

View source ↗

Summary

Phase 2 pilot studies evaluating the haemodynamic and metabolic effects of apelin and relaxin in cardiovascular disease and type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Type 2 Diabetes Mellitus

Drugs mentioned

• Apelin (apelin)
• Relaxin (Relaxin)

Snippet

Sponsor: Cambridge University Hospitals NHS Foundation Trust | Conditions: Cardiovascular Diseases, Type 2 Diabetes Mellitus | Phase 2 | Status: UNKNOWN